Inventor · disambiguated record
David H. Kirn
Also filed as: KIRN DAVID · KIRN DAVID H
35 granted patents·17 pending applications·243 citations·filing 1996–2024
97Inventor score
Files with4D MOLECULAR THERAPEUTICS INC23SILLAJEN BIOTHERAPEUTICS INC10KIRN DAVID9IGNITE IMMUNOTHERAPY INC3ONYX PHARMA INC3
Top patents by PatentIndex Score
52 records- 0197US11613766B2Adeno-associated virus variant capsids and methods of use thereof4D MOLECULAR THERAPEUTICS INC·Filed 2022·Granted Mar 28, 2023·4 cites·20 claims
- 0297US11167041B2Adeno-associated virus variant capsids and methods of use thereof4D MOLECULAR THERAPEUTICS INC·Filed 2020·Granted Nov 9, 2021·8 cites·6 claims
- 0397US9919062B2Oncolytic vaccinia virus cancer therapySILLAJEN BIOTHERAPEUTICS INC·Filed 2015·Granted Mar 20, 2018·30 cites·20 claims
- 0497US9226977B2Oncolytic vaccinia virus cancer therapySILLAJEN BIOTHERAPEUTICS INC·Filed 2015·Granted Jan 5, 2016·25 cites·20 claims
- 0596US11118192B2Adeno-associated virus variant capsids and methods of use thereof4D MOLECULAR THERAPEUTICS INC·Filed 2018·Granted Sep 14, 2021·15 cites·31 claims
- 0695US11802278B2Codon optimized GLA genes and uses thereof4D MOLECULAR THERAPEUTICS INC·Filed 2022·Granted Oct 31, 2023·3 cites·10 claims
- 0794US8980246B2Oncolytic vaccinia virus cancer therapyKIRN DAVID·Filed 2012·Granted Mar 17, 2015·17 cites·20 claims
- 0893US11198858B2Codon optimized GLA genes and uses thereof4D MOLECULAR THERAPEUTICS INC·Filed 2021·Granted Dec 14, 2021·2 cites·23 claims
- 0992US11345930B2Codon optimized RPGRORF15 genes and uses thereof4D MOLECULAR THERAPEUTICS INC·Filed 2021·Granted May 31, 2022·2 cites·25 claims
- 1092US8329164B2Methods and compositions concerning poxviruses and cancerKIRN DAVID·Filed 2007·Granted Dec 11, 2012·10 cites·9 claims
- 1190US11529402B2Recombinant vaccinia virus and methods of use thereofIGNITE IMMUNOTHERAPY INC·Filed 2020·Granted Dec 20, 2022·6 cites·9 claims
- 1289US8747837B2Oncolytic vaccinia virus combination cancer therapyKIRN DAVID·Filed 2010·Granted Jun 10, 2014·18 cites·15 claims
- 1388US11766489B2Adeno-associated virus variant capsids and use for inhibiting angiogenesis4D MOLECULAR THERAPEUTICS INC·Filed 2018·Granted Sep 26, 2023·5 cites·33 claims
- 1487US2024066145A1Adeno-associated virus variant capsids with improved retinal transduction and uses thereof4D MOLECULAR THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1587US2024358859A1Codon optimized rep1 genes and uses thereof4D MOLECULAR THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1686US11766487B2Treatments for retinal disease4D MOLECULAR THERAPEUTICS INC·Filed 2022·Granted Sep 26, 2023·0 cites·15 claims
- 1786US11685904B2Recombinant vaccinia virus and methods of use thereofIGNITE IMMUNOTHERAPY INC·Filed 2020·Granted Jun 27, 2023·5 cites·15 claims
- 1885US8986674B2Methods and compositions concerning poxviruses and cancerJENNEREX INC·Filed 2012·Granted Mar 24, 2015·5 cites·14 claims
- 1984US11840704B2Adeno-associated virus variant capsids and methods of use thereof4D MOLECULAR THERAPEUTICS INC·Filed 2022·Granted Dec 12, 2023·0 cites·20 claims
- 2083US11576983B2Treatments for retinal disease4D MOLECULAR THERAPEUTICS INC·Filed 2022·Granted Feb 14, 2023·0 cites·18 claims
- 2183US9180149B2Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxvirusesKIRN DAVID·Filed 2006·Granted Nov 10, 2015·4 cites·15 claims
- 2280US11524081B2Codon optimized REP1 genes and uses thereof4D MOLECULAR THERAPEUTICS INC·Filed 2022·Granted Dec 13, 2022·0 cites·20 claims
- 2380US9827278B2Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxvirusesSILLAJEN BIOTHERAPEUTICS INC·Filed 2015·Granted Nov 28, 2017·2 cites·23 claims
- 2479US9919047B2Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virusKIRN DAVID·Filed 2012·Granted Mar 20, 2018·5 cites·24 claims
- 2579US2024018498A1Codon optimized gla genes and uses thereof4D MOLECULAR THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2679US2023158172A1Codon optimized rep1 genes and uses thereof4D MOLECULAR THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2778US12221616B2Adeno-associated virus variant capsids and methods of use thereof4D MOLECULAR THERAPEUTICS INC·Filed 2021·Granted Feb 11, 2025·0 cites·20 claims
- 2878US11357870B2Codon optimized REP1 genes and uses thereof4D MOLECULAR THERAPEUTICS INC·Filed 2021·Granted Jun 14, 2022·0 cites·25 claims
- 2977US11419949B2Adeno-associated virus variant capsids and methods of use thereof4D MOLECULAR THERAPEUTICS INC·Filed 2021·Granted Aug 23, 2022·0 cites·6 claims
- 3076US11179477B2Method of using adeno-associated virus with variant capsid4D MOLECULAR THERAPEUTICS INC·Filed 2020·Granted Nov 23, 2021·0 cites·6 claims
- 3175US2021322578A1Oncolytic vaccinia virus cancer therapySILLAJEN BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3274US9719105B2Methods and compositions for production of vaccinia virusKIRN DAVID·Filed 2012·Granted Aug 1, 2017·2 cites·27 claims
- 3374US9180151B2Oncolytic vaccinia virus combination cancer therapySILLAJEN BIOTHERAPEUTICS INC·Filed 2014·Granted Nov 10, 2015·2 cites·22 claims
- 3472US11364308B2Adeno-associated virus variant capsids and methods of use thereof4D MOLECULAR THERAPEUTICS INC·Filed 2017·Granted Jun 21, 2022·0 cites·15 claims
- 3572US10434169B2Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virusSILLAJEN BIOTHERAPEUTICS INC·Filed 2018·Granted Oct 8, 2019·1 cites·13 claims
- 3669US10767166B2Methods and compositions for production of vaccina virusSILLAJEN BIOTHERAPEUTICS INC·Filed 2019·Granted Sep 8, 2020·0 cites·19 claims
- 3768US6296845B1Selective killing and diagnosis of p53+ neoplastic cellsONYX PHARMA INC·Filed 1998·Granted Oct 2, 2001·31 cites·12 claims
- 3868US2020009269A1Oncolytic vaccinia virus cancer therapySILLAJEN BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3968US2022290181A1Codon optimized rpgrorf15 genes and uses thereof4D MOLECULAR THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4067US2025163469A1Adeno-associated virus variant capsids and methods of use thereof4D MOLECULAR THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4164US2024335560A1Adeno-associated virus variant capsids and use for inhibiting angiogenesis4D MOLECULAR THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4264US2018256751A1Oncolytic vaccinia virus cancer therapySILLAJEN BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4362US6133243ALiposomal-viral DNA complexes for treating diseaseONYX PHARMA INC·Filed 1996·Granted Oct 17, 2000·17 cites·10 claims
- 4460US2010303714A1Oncolytic vaccinia virus cancer therapyKIRN DAVID·Filed 2008·Application pending·0 cites
- 4560US2006099224A1Methods and compositions concerning poxviruses and cancerKIRN DAVID·Filed 2003·Application pending·0 cites
- 4659US2008286237A1Systemic Treatment of Metastatic and/or Systemically-Disseminated Cancers using GM-CSF-Expressing PoxvirusesKIRN DAVID·Filed 2007·Application pending·0 cites
- 4757US6080578ACytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasiaONYX PHARMA INC·Filed 1997·Granted Jun 27, 2000·24 cites·10 claims
- 4854US10202581B2Methods and compositions for production of vaccinia virusSILLAJEN BIOTHERAPEUTICS INC·Filed 2017·Granted Feb 12, 2019·0 cites·19 claims
- 4949US2023201283A1Recombinant vaccinia virusPFIZER·Filed 2021·Application pending·0 cites
- 5048US2023002740A1Variant oncolytic vaccinia virus and methods of use thereofIGNITE IMMUNOTHERAPY INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David H. Kirn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →